Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Ulcerative Colitis
Interventions
DRUG

AEB071

DRUG

Placebo

Trial Locations (20)

10117

Novartis Investigative Site, Berlin

21339

Novartis Investigative Site, Lüneburg

22559

Novartis Investigative Site, Hamburg

24105

Novartis Investigative Site, Kiel

30625

Novartis Investigative Site, Hanover

32423

Novartis Investigative Site, Minden

36608

Novartis Investigative Site, Mobile

48047

Novartis Investigative Site, Chesterfield Twp

48098

Novartis Investigative Site, Troy

66606

Novartis Investigative Site, Topeka

70376

Novartis Investigative Site, Stuttgart

70501

Novartis Investigative Site, Lafayette

73104

Novartis Investigative Site, Oklahoma City

85213

Novartis Investigative Site, Mesa

93053

Novartis Investigative Site, Regensburg

DK-8000

Novartis Investigative Site, Aarhus

DK-5000

Novartis Investigative Site, Odense C

04105

Novartis Investigative Site, Leipzig

30-307

Novartis Investigative Site, Krakow

60-539

Novartis Investigative Site, Poznan

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY